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 At a Glance Commentary 
Scientific Knowledge on the Subject 
There is significant heterogeneity in the septic response, which has hindered efforts to 
understand pathophysiology and develop targeted therapies. Molecular approaches may provide 
insights into variation in the host response, enabling biomarker development. Recent evidence 
suggests transcriptomic sepsis response signatures (SRS) can define patient subgroups associated 
with early outcome in sepsis due to community acquired pneumonia (CAP). 
What This Study Adds to the Field 
This study provides the first substantive analysis of the transcriptomic response in patients 
admitted to intensive care with sepsis due to fecal peritonitis (FP). Comparison with sepsis due to 
CAP and with non-septic controls demonstrates a shared sepsis response, independent of source 
of infection, which involves a significant proportion of the transcribed genome and overlaps with 
the “genomic storm” following trauma. We find evidence of SRS groups in FP patients 
predictive of early mortality, with group membership changing over time in some patients. We 
show that the major predictor of variation in gene expression between sepsis patients is SRS 
group rather than source of infection, with only a small number of genes differentially regulated 
according to the latter, enriched for interferon signaling and antigen presentation. These findings 
highlight opportunities for patient stratification in sepsis.  
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org.
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Abstract 
Rationale:  Heterogeneity in the septic response has hindered efforts to understand 
pathophysiology and develop targeted therapies. Source of infection, with different causative 
organisms and temporal changes, might influence this heterogeneity.  
Objectives: To investigate individual and temporal variation in the transcriptomic response to 
sepsis due to fecal peritonitis, and to compare with community acquired pneumonia. 
Methods: We performed genome-wide gene expression profiling in peripheral blood leukocytes 
for adult patients admitted to intensive care with sepsis due to fecal peritonitis (n=117) or 
community acquired pneumonia (n=126), and non-septic controls (n=10). 
Measurements and Main Results: A substantial portion of the transcribed genome (18%) was 
differentially expressed compared to controls, independent of source of infection, with EIF2 
signaling the most enriched canonical pathway. We identify two sepsis response signature 
subgroups in fecal peritonitis associated with early mortality (p-value=0.01, hazard ratio=4.78). 
We define gene sets predictive of SRS group, and serial sampling demonstrates subgroup 
membership is dynamic during ICU admission. We find SRS is the major predictor of 
transcriptomic variation; a small number of genes (n=263) were differentially regulated 
according to the source of infection, enriched for interferon signaling and antigen presentation. 
We define temporal changes in gene expression from disease onset involving phagosome 
formation, NK cell and IL-3 signaling. 
Conclusions: The majority of the sepsis transcriptomic response is independent of source of 
infection and includes signatures reflecting immune response state and prognosis. A modest 
number of genes show evidence of specificity. Our findings highlight opportunities for patient 
stratification and precision medicine in sepsis.  
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Introduction 
Sepsis is the life-threatening organ dysfunction caused by a dysregulated host response to 
infection (1). Therapeutic options remain limited despite extensive efforts to develop and refine 
treatment strategies (2). New insights into pathophysiology and the development of targeted 
treatments appropriate for individual patients at specific stages in the illness are urgently 
required (3). To be successful, this approach requires clearer understanding of heterogeneity in 
the sepsis response, in which pro-inflammatory and immunosuppressed states are dynamic and 
frequently co-exist (4). We recently identified distinct transcriptomic sepsis response signatures 
(SRS) in peripheral blood leukocytes from patients with community acquired pneumonia (CAP), 
informative for immune response states and outcome (5). In particular, patients with SRS1 
exhibit an immunosuppressed phenotype associated with higher early mortality, with features of 
endotoxin tolerance, T-cell exhaustion and downregulation of HLA class II. 
 It is not yet known whether comparable SRS are present in sepsis caused by other sources of 
infection. Additionally, the extent to which the source of infection contributes to heterogeneity in 
the transcriptomic response is unclear, although there is evidence that gene expression signatures 
can distinguish between Gram positive, Gram negative and viral etiologies, and may be useful in 
the diagnosis of CAP (6-13). In fecal peritonitis (FP), sepsis is triggered by a poly-microbial 
infection within the peritoneal cavity, complicated by the release of damage associated molecular 
patterns (DAMPS) and the effects of anaesthesia (14). Conversely, CAP is caused by specific 
bacterial or atypical pathogens, and is commonly preceded or caused by viral infection (15). 
Antibiotic choice, for example macrolides for CAP, may also have immunomodulatory effects 
(16, 17). Finally, while FP patients usually have a rapid onset of illness, CAP patients are often 
unwell for many days prior to ICU admission.  
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FP is a common cause of sepsis with a high mortality (18), in which longitudinal analysis is 
tractable given that a defined time of onset can be estimated. We hypothesized that sepsis 
response signatures similar to those seen in CAP would be present in FP patients but that aspects 
of the transcriptomic host response would be dependent on the source of infection and stage of 
illness. Here, we investigate how patterns of gene expression in leukocytes are influenced by 
source of infection for FP and CAP, and how they vary between individual patients and within 
patients over time.  
 
Some of the results of these studies have been previously reported in the form of abstracts (19, 
20). 
 
Methods 
Study design and participants 
The objective was to characterize the transcriptomic response to sepsis caused by FP, including 
an analysis of temporal changes and a comparison with sepsis caused by CAP. The subjects were 
adult patients admitted to ICU with sepsis as part of the UK GAinS study (www.ukccg-
gains.org) with pre-defined inclusion and exclusion criteria (described in online data 
supplement). FP was diagnosed at laparotomy as inflammation of the peritoneal membrane 
secondary to large bowel perforation and fecal contamination (18). CAP was defined as a febrile 
illness associated with cough, sputum production, breathlessness, leukocytosis and radiological 
features of pneumonia, acquired in the community or within two days of ICU admission (21, 22). 
This was a prospective observational study. The transcriptomic response was investigated in 
peripheral blood leukocytes and compared between patients and over time, and with controls 
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undergoing elective cardiac surgery (described in online data supplement). Discovery and 
validation cohorts were used to identify shared and specific gene expression patterns among FP 
and CAP patients (Supplementary Fig E1). 
  
Sample Collection 
Blood samples (5ml) were collected (Vacuette EDTA tubes) on the first, third, and/or fifth day 
after ICU admission. The total blood leukocyte population was isolated using LeukoLOCK 
filters (Ambion), stabilized using RNAlater, and total RNA extracted (described in online data 
supplement). Extensive, anonymized clinical information was recorded using an electronic Case 
Report Form (eCRF) (5).  
 
Microarray analysis 
Genome-wide gene expression was quantified using Illumina Human-HT-12 v4 Expression 
BeadChips (47,231 probes) with sample processing, data preparation, background subtraction, 
transformation and normalization using the vsn package (23) (described in the online data 
supplement). Gene expression data is available through ArrayExpress (accession: E-MTAB-
5273/E-MTAB-5274). 
 
Statistical analysis 
Analysis was carried out using R unless otherwise specified, with statistical tests, power 
calculations, differential gene expression, enrichment testing, predictive modelling, and cluster 
analysis described in the online data supplement. 
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Results 
Transcriptomic response to fecal peritonitis: identification of sepsis response signatures 
We quantified genome-wide gene expression for 117 FP and 126 CAP adult patients admitted to 
ICU with sepsis, analyzing RNA from blood leukocytes rapidly isolated at the bedside. All 
patients showed evidence of organ dysfunction based on SOFA scores during ICU admission. 
These patients were recruited concurrently and processed in parallel as discovery (64 FP, 73 
CAP) and validation cohorts (53 FP, 53 CAP) (these 53 CAP cases were previously published 
(5)). We also analyzed samples obtained from ten subjects prior to elective cardiac surgery as 
non-septic controls in the discovery cohort. Demographics and clinical covariates for the 
discovery set (FP n=64, CAP n=73 patients; 221 samples, Supplementary Fig. E1) are shown 
(Table 1, Supplementary Table E1A). 
 
We investigated whether sepsis response subgroups based on global patterns of gene expression 
were present in FP. The combined FP cohort (147 samples from 117 patients) had a 28-day 
mortality of 13%; the mean age was 66 years and 50.4% of patients were male (Table 2, 
Supplementary Table E1B). We applied two complementary approaches to this FP cohort: (1) 
hypothesis-free unsupervised hierarchical clustering based on observed patterns of variation in 
gene expression and (2) assignment based on expression of a specific seven gene set previously 
shown to be predictive of SRS group membership in CAP (5).  
 
We first analyzed variation in global gene expression (2716 probes, 10% most variably 
expressed genes) using agglomerative hierarchical clustering followed by consolidation of group 
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membership using k-means. This approach revealed two distinct patient groups, SRS1_FP 
(n=68, 46%) and SRS2_FP (n=79, 54%) (Fig.1 A, B). Following group assignment, 1075 genes 
were found to be differentially expressed between these groups (Fig. 1C, Supplementary Table 
E1C), showing strong correlation with those previously observed in CAP patients (5) (Pearson’s 
r=0.791; Supplementary Fig. E2). To determine the functional overlap with SRS groups 
identified in CAP, we performed pathway, function enrichment, and upstream regulator analysis 
(Fig. 1D, Supplementary Table E1D). Cell death, apoptosis, necrosis, T cell activation, and 
endotoxin tolerance were significantly enriched biological functions in SRS1 for both sources of 
infection. We proceeded to test for association with outcome in FP, and found that SRS1_FP 
group membership was associated with higher early mortality (14 day mortality log rank test 
P=0.0096, 18.8% vs 4.3%, HR=4.78 (1.29-17.65)) (Fig. 1E). The effect of SRS group 
membership remained after inclusion of age, SOFA score, Charlson Comorbidity Index, and sex 
in a cox proportional hazards model (p=0.037, HR=4.23 (1.09-16.39)).  
 
To further validate our findings, we adopted a second approach, namely assignment of SRS 
group membership in this FP cohort using the seven gene set (DYRK2, CCNB1IP1, TDRD9, 
ZAP70, ARL14EP, MDC1 and ADGRE3) we previously established in CAP patients (5) 
(Supplementary Fig. E3). This showed strong concordance with the results obtained by 
unsupervised analysis (misclassification rate 21.1%, AUC 0.923; Fig. 1F). The groups defined 
using the seven gene set showed a significant difference in early mortality rates (log rank test 
P=0.030 FP patients), a differential gene expression signature strongly correlated with that seen 
in the original CAP analysis (r=0.845), and pathway enrichment comparable to findings in CAP 
patients. We also derived a six gene set (CD163, ZDHHC19, MME, FAM89A, ZBP1, B3GNT2) 
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from the FP data predictive of SRS_FP group membership, with a 4.1% misclassification rate 
based on internal leave-one-out cross-validation (AUC 0.975; Fig. 1F). When applied to the 
original CAP cohort (5), this six gene set again performed well (misclassification rate 27.9%, 
AUC 0.931). 
 
A poor outcome subgroup has previously been reported in children with sepsis (24). We 
investigated the similarity between pediatric endotype A and SRS1 by comparative differential 
gene expression analysis. Although there was some overlap in pathway enrichment (e.g. T and B 
cell receptor signaling), the gene expression patterns that distinguish SRS groups were not 
enriched in the pediatric endotype contrast (Supplementary Fig. E4).  
 
Temporal changes in sepsis response signatures 
Serial sampling on day 1, day 3, and day 5 following ICU admission provides the opportunity to 
investigate the relationship between SRS group membership and disease progression. We found 
that 11 out of 24 FP patients (46%) with serial samples moved between groups over time; 10 
from SRS1 to SRS2, of whom only 1 died (Fig. 1G). Thirteen patients (54%) remained in the 
same SRS group; 3/7 patients remaining in SRS1 died, compared to no deaths amongst the 6 
remaining in SRS2. This movement between SRS groups involves large changes in gene 
expression, illustrated by CD163, encoding an innate immune sensor for bacteria, and one of the 
six gene classifiers for SRS_FP (Fig. 1H, Supplementary Fig. E5). 
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Influence of source of infection on the transcriptomic response  
We proceeded to further characterize and compare gene expression in FP and CAP patients to 
determine the relative importance of shared and specific features of the transcriptomic response. 
As expected, in the discovery cohort GI-related comorbidities were more common in FP patients, 
while CAP patients had more respiratory comorbidities, higher respiratory rate and oxygenation 
requirements, and a higher lymphocyte count (Table 1 and Supplementary Table E1A). Although 
mortality did not differ significantly, CAP patients had higher APACHE and SOFA scores 
(Table 1).  
 
To understand the relationships between source of infection, SRS group, and heterogeneity in the 
septic response we performed principal component analysis using the top 10% most variably 
expressed transcripts. Non-septic controls cluster together and are clearly distinct from septic 
patients (Fig. 2A). Among the combined population of septic patients, there was clear 
segregation based on SRS group but not source of infection (Fig. 2A).  
 
In order to further elucidate the drivers of variation in the septic response, we calculated 
correlations between the observed variance in global gene expression for the sepsis samples (the 
first six principal components of variance, representing ~50% of the variance in the data), a 
comprehensive set of clinical covariates, and SRS group (Fig. 2B, Supplementary Table E1E). 
This showed variation in gene expression was most strongly correlated with SRS group 
membership (PC1: r=0.77, FDR=<2.2x10
-16
). More modest correlation was seen with source of 
infection (PC1: r=-0.417, FDR=6.12x10
-9
), bicarbonate levels (PC1: r=0.35, FDR=2.2x10
-8
) and 
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neutrophil count (PC1: r=-0.29, FDR=2.0x10
-3
). When the dataset was divided into CAP and FP 
samples and the analysis repeated, we found SRS remained the most significant correlate 
(Supplementary Fig. E6).  
 
When we compared all patients in the discovery cohort (FP n=64, CAP n=73) with non-septic 
controls (n=10) we found that sepsis was associated with differential regulation of a large 
proportion of the transcribed genome (18.0% of transcripts assayed, 4881 probes; >1.5 fold 
change (FC), FDR <0.05; Supplementary Table E1F). Pathway analysis showed EIF2 signaling 
was the top canonical pathway, consistent with the reported role for this translational initiation 
factor in response to viral and bacterial infection (25), and predicted key upstream regulators 
IL13, ATB1, TGFB1 and IL2 (Supplementary Table E1G). Using the same methodology, we 
contrasted global gene expression differences in sepsis compared to controls with those observed 
in the previously published genomic response to trauma versus healthy subjects (26) within the 
same time frame as the sepsis cohort (5 days following injury). We found that of the genes 
differentially expressed in the sepsis response and measured in the trauma cohort, the majority 
(n=1884, 64%) were also differentially expressed (Fig. 2C). Commonality was seen with EIF2 
signaling and inflammation-related pathways enriched in both sepsis and trauma responses, 
while the inflammatory response to organismal injury was specific to trauma, and TNFR1 
signaling to sepsis (Fig. 2C, Supplementary Table E1H).  
 
When we compared CAP vs controls and FP vs controls, gene expression patterns were highly 
correlated, demonstrating that most sepsis response pathways are common and independent of 
source of infection (Fig. 2D, 3A, B; Supplementary Table E1I, J).  
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To further investigate differential gene expression between patients with sepsis due to FP or 
CAP, we compared the first available samples for each patient following ICU admission (FP 
n=64, CAP n=73). We found 310 probes (263 genes) differentially expressed between the two 
sources of infection (FC >1.5, FDR <0.05; Fig. 3C, Supplementary Table E1K), significantly 
more than expected by chance based on permutation analysis (Supplementary Fig. E7). We noted 
significant differences in total and differential cell counts between CAP and FP. The inclusion of 
differential cell counts in the regression model had minimal influence, with a similar list of 
differentially regulated genes and fold changes strongly correlated with the original analysis 
(Supplementary Fig. E8, Supplementary Table E1K). IFN signaling (P 6.1x10
-10
) and antigen 
presentation (P 1.6x10
-8
) were the most significant enriched canonical pathways, upregulated in 
CAP patients compared to FP (Fig. 3D, Supplementary Table E1L). Enriched networks involved 
IFNα/β and the antimicrobial/inflammatory response (P 1x10
-39
) (Fig. 3E). IFIT1, IFIT2, and 
IFIT3 (interferon-induced antiviral genes), BTN3A3 (MHC class I gene), IFIH1 (sensor of viral 
nucleic acids) and OAS2 (interferon-induced antiviral enzyme) were all up-regulated in CAP 
patients.  IFNs, endotoxin and TNF were found to be significant upstream regulators (Fig. 3D, 
Supplementary Table E1L).  
 
We confirmed our findings in a validation set comprising 53 FP and 53 CAP patients 
prospectively recruited to the UK GAinS study (Supplementary Fig. E1). We found SRS group, 
source of infection, cell count, and day of sampling were strongly associated with the first six 
principal components of gene expression; genes differentially expressed between FP/CAP 
correlated with those found in the discovery cohort (Pearson’s r=0.83, P < 2.2x10
-16
; 
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Supplementary Table E1M). Pathway analysis demonstrated high concordance of enriched 
pathways and functions (Fig. 3D, Supplementary Table E1N). We found a gene set comprising 
EPHB1, NQO2, ARG1, HMGB2, FGL2, and GPR162 was predictive of source of infection (FP 
or CAP) for the discovery cohort. We applied a sparse regression method to show that for the 
discovery cohort the misclassification rate was 29.9% with internal leave-one-out validation 
(AUC 0.760); for the validation cohort the test error was 28.3% (AUC 0.798; Supplementary Fig 
E9). There was no difference in the proportion of different sampling days following ICU 
admission between FP and CAP samples in the analyzed cohorts (Supplementary Fig. E10, chi-
square P=0.350). 
 
Given a prominent viral signature amongst genes differentially expressed between FP and CAP 
patients, we investigated if this came from a subset of CAP patients with a viral infection. Only 
6/73 CAP patients in the discovery cohort had a confirmed viral infection; we therefore analyzed 
the transcriptomic differences between patients with and without confirmed viral infection in our 
larger previously published CAP cohort (25 vs 240 patients)  (5). We identified 39 differentially 
expressed genes (FDR <0.05, FC >1.5) (Fig. 3F, Table E1O) including IFI27, an interferon 
alpha-inducible protein reported as a marker of influenza infection (27); and LAMP3, a dendritic 
cell glycoprotein induced by influenza A infection (28). Pathway analysis showed most 
significant enrichment for pattern recognition receptors, IFN signaling and IRFs (Supplementary 
Table E1P). We then compared this gene set to the genes differentially expressed between FP 
and CAP patients and found significant enrichment of 24/39 genes (P <1x10
-4
). 
 
Temporal changes in gene expression  
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Interpretation of gene expression patterns in sepsis may be complicated by dynamic differences 
in the host response over time (10, 29). We explored temporal changes in gene expression for FP 
and CAP patients in whom serial samples following ICU admission were available. We first 
sought to identify genes that varied over time using a repeated measures regression model. We 
found 714 genes were significantly differentially expressed in FP sepsis patients between days 1 
and 5, compared to only 80 genes in CAP patients (FDR <0.05, FC >1.5) (Fig. 4A, 
Supplementary Table E1Q). We further analyzed our data using a multivariate empirical Bayes' 
model, which ranks genes based on differential expression for longitudinal series involving 
multiple biological conditions (30), restricting this analysis to patients where samples were 
available at all 3 time points. Notably, temporal changes in gene expression were again more 
pronounced in FP patients (Supplementary Table E1R), and the specific genes whose expression 
changed over time differed between FP and CAP (Fig. 4B,C).  
 
In FP patients it was possible to estimate with reasonable accuracy the time of onset of the acute 
event. We calculated days from disease onset for each FP sample and used this to investigate 
temporal changes. We found that using a linear model with limma analysis, 140 genes show 
significant changes in expression over time (FDR <0.05) (Supplementary Table E1S) including 
AAK1 and SNN (Fig. 4D). Pathway analysis was significant for genes involved in phagosome 
formation, NK cell and IL-3 signaling with evidence of enrichment for specific biological 
functions notably cellular degranulation, chemotaxis, leukocyte activation, macrophage 
adhesion, phagocytosis and bacterial infection (Supplementary Table E1T). 
 
Page 16 of 54 AJRCCM Articles in Press. Published on 30-December-2016 as 10.1164/rccm.201608-1685OC 
 Copyright © 2016 by the American Thoracic Society 
 15 
Discussion 
We have characterised the transcriptomic response to sepsis caused by FP and found evidence of 
sepsis response signatures associated with outcome, patients in SRS1 having higher early 
mortality. Transcriptomic features of endotoxin tolerance and pathway enrichment for cell death, 
apoptosis, necrosis and T cell exhaustion are consistent with animal models and human studies 
demonstrating the importance of immune compromise in sepsis pathogenesis and as a 
determinant of poor outcomes (4, 31, 32). The FP dataset allowed us to explore evolution of SRS 
membership. We find a significant number of patients (46%) switch SRS group in the first 5 
days of ICU admission, the majority moving from SRS1 to SRS2. Persistence of SRS1 is 
associated with a poor outcome whereas maintenance or recovery of immune competence 
(SRS2) is associated with survival. These findings further support the concept that SRS group 
membership reflects clinically important biological differences (5) and suggest that if used as a 
biomarker, the transcriptomic response signature should be determined at the time a therapeutic 
intervention is being considered. Establishing the immune response state of a patient could 
enable individually tailored immunotherapy and monitoring the response to treatment. 
 
We found that the transcriptomic response is, to a large extent, shared between the two sources 
of infection analysed here, with the expression of only a modest number of genes being 
dependent on source of infection. This shared sepsis response involves a significant proportion of 
the transcribed genome and overlapped with the “genomic storm” following trauma although we 
observed some differences for example involving TNFR1 signaling (26). Comparing gene 
expression between FP and CAP, the most enriched networks involved IFNα/β and the 
antimicrobial/inflammatory response. These differences seem to be predominantly driven by 
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viral respiratory infection within the CAP cohort, although given current difficulties in pathogen 
detection the biological and clinical interpretation of such transcriptomic differences remains 
challenging. While some previous studies have supported a common transcriptional septic 
response independent of pathogen (33), others have reported that expression signatures can 
discriminate between infecting organisms (6-8, 13) although these findings remain controversial 
(9, 10). For patients admitted to ICU with suspected CAP, a 78 transcript signature has been 
reported to differentiate cases of CAP from non-CAP with the FAIM3:PLAC8 gene expression 
ratio proposed as a diagnostic biomarker (11). 
 
We found temporal changes were more pronounced in FP, with more than eight times as many 
genes differentially expressed between admission and day 5 than in CAP patients, and involved 
phagosome formation, NK cell signaling, IL-3 signaling, leukocyte activation, mitochondrial 
damage, and apoptosis. To date, time series analyzing changes in gene expression have focused 
on animal models of sepsis (34), the endotoxin response in healthy volunteers (35), the response 
to trauma and subsequent infection (26), and early events in sepsis (29), with a recent analysis of 
time-matched cohorts defining a gene set distinguishing sterile inflammation from infectious 
inflammation (12). In general, clearer resolution of temporal differences will be critical to 
resolving heterogeneity in observed sepsis responses within and between patients. 
 
Future work should include comprehensive pathogen phenotyping, for example using 
metagenomic sequencing, given the recognized high proportion of culture-negative patients in 
sepsis (36, 37). Comparison of FP patients with specific controls, such as a group of patients 
undergoing laparotomy for non-infectious indications would control for the effects of DAMP-
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mediated signaling from the surgical procedure, and any modulating influences on the 
transcriptome from general anesthesia, while inclusion of patients undergoing laparotomy for 
gastric or small-bowel perforation would to some extent control for different pathogens. 
Differences in differential cell count are potential confounders in transcriptomic analysis (10) 
and, although the results presented were robust to differential leukocyte count, cell type-specific 
transcriptomic profiling will be important for future studies (38). 
 
Defining the most robust and informative predictive gene set for SRS membership based on 
transcriptomics will require prospective large-scale validation using an appropriate point of care 
test. We note that the current seven gene set established in CAP patients and validated in FP is 
consistent with a key role for a dysfunctional immune response in sepsis. This predictive gene set 
includes genes involved in cell growth (DYRK2), cell cycle (CCNB1IP1), stem cell maintenance 
(TDRD9) and DNA damage (ADGRE3), consistent with the observed pathway enrichment (cell 
death, apoptosis, necrosis); and with immune response through lymphocyte activation (ZAP70), 
MHC class II export (ARL14EP) and myeloid cell interactions in immunity (MDC1). The lack of 
overlap with paediatric sepsis endotypes we observed requires further validation and may reflect 
developmental differences impacting on pathophysiology and host immune dysfunction (39, 40). 
 
We have addressed sepsis heterogeneity using a transcriptomic approach in patients with FP and 
CAP, demonstrating a shared sepsis response with distinct SRS groups that are dynamic, reflect 
the underlying biological response, and are informative for prognosis. Our findings also provide 
some evidence for differential patterns of expression between CAP and FP, two of the most 
common causes of sepsis. Our analysis, coupled with recent advances in the field (3, 4, 11, 41), 
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highlights the opportunity to develop novel therapeutic interventions that can be targeted and 
appropriately timed to individual patients based on transcriptomic signatures, providing 
opportunities for precision medicine in sepsis. 
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Figure legends 
Fig. 1: Transcriptomic sepsis response signatures in FP. (A) Unsupervised hierarchical 
clustering analysis of 147 FP samples for the top 10% most variable probes (n=2716). (B) First 
three principal components plotted with the proportion of variance explained by each 
component, with samples colored by SRS group membership assigned by hierarchical and k-
means clustering. (C) Volcano plot of differentially expressed probes for SRS1_FP vs SRS2_FP 
(red coloring shows fold change > 1.5, false discovery rate < 0.05). (D) Enriched functions, 
disease phenotypes, and predicted upstream regulators derived from differentially expressed 
probes in FP SRS groups and compared with the previously published CAP dataset. Enrichment 
was also seen for an endotoxin tolerance gene expression signature we previously defined(5) 
from publically available datasets(42, 43) in SRS1_FP relative to SRS2_FP tested using ROAST, 
a gene set enrichment test (P<1x10
-5
) (E) Kaplan-Meier survival plot by SRS group (95% 
confidence intervals shaded) with a single sample selected at random for those patients with 
multiple samples to assign SRS membership. (F) The performance of the SRS group assignment 
models (gene sets) derived using and tested in the FP and previously published CAP datasets are 
shown by receiver operator characteristic (ROC) curves and the area under the curve (AUC) 
given for each. (G) Time course of patient SRS-FP group membership using serial samples and 
days from disease onset. (H) Expression of CD163 over time from disease onset in samples from 
the 11 FP patients who move between SRS groups. Each point represents a sample, colored 
according to SRS group assignment, with lines linking samples from the same patient. 
 
Fig. 2: Transcriptomic response to sepsis. (A) First two principal components of gene 
expression data plotted with the proportion of variance explained by each component shown. 
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Filled circles represent FP discovery samples (n=94), open circles represent CAP discovery 
samples (n=127). Samples are colored according to SRS group assignment, showing that sepsis 
response states show considerable overlap between sources of infection. Controls (n=10) are 
indicated by crosses. (B) Heatmap showing correlation between the first six principal 
components, SRS and clinical covariates for sepsis samples (FP n=94, CAP n=127). (C) Venn 
diagram showing the overlap in differential gene expression vs. controls in the sepsis response 
and the response to trauma (FDR < 0.05, FC > 1.5; first five days). Selected condition-specific 
enriched pathways and biological functions are noted. (D) Volcano plot of differentially 
expressed probes for FP (n=94) (left) and CAP (n=127) (right) vs controls (n=10) (red coloring 
shows FC > 1.5, FDR < 0.05). 
 
Fig. 3: Variation in the sepsis transcriptome according to source of infection. (A) Venn 
diagram showing the overlap in the FP and CAP sepsis response in terms of the number of 
differentially expressed genes vs. controls (FP n=64 samples, CAP n=73 samples, Controls n=10 
samples). (B) Correlation of differential gene expression between sepsis due to FP (n=64 
samples) and controls (n=10 samples), and sepsis due to CAP (n=73 samples) and controls (n=10 
samples). (C) Volcano plot of differentially expressed probes for CAP vs FP (red coloring shows 
FC >1.5, FDR <0.05, positive fold change indicates relative upregulation in CAP). (D) Enriched 
pathways and predicted upstream regulators derived from differentially expressed genes for CAP 
vs FP in the discovery (CAP n=73 samples, FP n=64 samples) and validation cohorts (CAP n=53 
samples, FP n=53 samples). (E) Most significantly enriched network (P 1x10
-39
) on comparison 
of CAP vs FP with differentially expressed genes shaded (red upregulation, green 
downregulation) and log fold change with P value shown for each gene. (F) Volcano plot of the 
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differentially expressed probes for positive viral diagnosis (n=25) vs no positive viral diagnosis 
(n=240) in 265 CAP patients. Red coloring indicates FC >1.5, FDR <0.05. 
 
Fig. 4: Dynamics of gene expression in sepsis due to FP and CAP. (A) Volcano plot of the 
differentially expressed probes for Day 1 vs 5 samples from the same patient in FP (n=9) (left) 
and CAP (right) (n=17) (red coloring indicates FC >1.5 and FDR <0.05). (B) Examples of genes 
showing significant temporal variation in expression over time for patients with sepsis due to FP 
included the kinase activator CDK5R1 and complement component C1QB; other examples are 
the adhesion receptor EMR3 and cysteine protease CAPN13. (C) Examples of genes showing 
variation in expression over time for patients with sepsis due to CAP included cell cycle genes 
NIT2 and the hematopoiesis regulatory transcription factor gene MYB; other examples are the 
antimicrobial neutrophil peptidase CTSG, inflammatory regulator CAMP, defensin DEFA4 and 
neutrophil granule elastase ELANE (D) Further examples of genes differentially expressed in FP 
over time plotted from time of onset of FP include the AP2 associated kinase 1 AAK1 involved in 
regulating clathrin-mediated endocytosis (44), critical for bacterial entry (45); and SNN encoding 
stannin, a mitochondrial damage sensor (46). 
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Discovery cohort Validation cohort 
CAP (n=73) FP (n=64) p value CAP (n=53) FP (n=53) p value 
Age (years) 60.6 (15.6) 65.1 (17.5) NS 68.4 (13.7) 68 (12.7) NS 
Male sex 37 (50.6%) 28 (43.7%) NS 37 (69.8%) 31 (58.5%) NS 
APACHE II score 18 (6.2) 15 (5.9) 0.005 19.7 (6.1) 15.7 (5.9) 0.0008 
SOFA score 6.8 (3.5) 5.4 (4.0) 0.03 6.2 (3.8) 6.3 (3.5) NS 
Mortality             
   14 days 8 (11.0%) 6 (9.4%) NS
†
 7 (13.2%) 6 (11.3%) NS
†
 
   28 days 13 (17.8) 8 (12.5%) NS
†
 7 (13.2%) 7 (13.2%) NS
†
 
   6 months 17 (23.3%) 11 (17.2%) NS
†
 11 (20.8%) 12 (22.6%) NS
†
 
Infection 
   Gram-positive bacteria 14 (19.2%)   7 (13.2%)   
   Gram-negative bacteria 8 (11.0%)     5 (9.4%)     
   Viral 6 (8.2%)     5 (9.4%)     
Mechanical Ventilation 51 (69.9%) 34 (53.1%) 0.05 19 (35.8%) 21 (39.6%) NS 
Respiratory Rate 29.2 (9.2) 20.0 (8.2) <0.0001 31.1 (8.7) 22.7 (9.0) <0.0001 
Days of Respiratory Support 9.6 (13.5) 4.7 (8.1) 0.01 8.8 (12.1) 9.3 (14.8) NS 
Oxygenation Index 19.3 (9.9) 30.9 (12.3) <0.0001 21.2 (7.5) 28.2 (12.2) <0.0001 
Vasopressors/inotropes     NS     NS 
   No dose 37 (50.7%) 35 (54.7%)   36 (67.9%) 27 (50.9%)   
   Low dose 1 (1.4%) 1 (1.6%)   0 (0%) 0 (0%)   
   Medium dose 10 (13.7%) 5 (7.8%)   7 (13.2%) 6 (11.3%)   
   High dose 24 (32.9%) 23 (35.9%)   10 (18.9%) 20 (37.7%)   
Mean arterial pressure (lowest, 
mmHg) 65.0 (12.8) 67.7 (12.5) NS 69.6 (11.1) 67.5 (14.6) NS 
Temperature (low) 36.4 (0.8) 36.1 (0.7) 0.018 36.0 (1.0) 36.1 (0.6) NS 
Hematocrit 35.4 (6.9) 30 (5.9) <0.0001 35.0 (7.9) 31.5 (6.6) 0.02 
Proportion of leukocytes             
   Lymphocytes 9.17% 6.52% 0.008 9.05% 8.77% NS 
   Polynucleocytes 84.10% 87.98% 0.029 83.40% 85.30% NS 
   Mononucleocytes 6.73% 5.50% NS 7.51% 5.95% NS 
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Bicarbonate 25.0 (6.8) 22.1 (5.1) 0.008 24.6 (6.8) 23.1 (5.0) NS 
Renal replacement therapy  6 (8.2%) 5 (7.8%) NS 5 (9.4%) 8 (15.1%) NS 
 
 
Table 1: Comparison of clinical characteristics of sepsis patients based on source of infection in the discovery and validation 
cohorts. Data are n (%) or mean (SD) unless otherwise specified. APACHE II = Acute Physiology and Chronic Healthy Evaluation II. 
SOFA=Sequential Organ Failure Assessment on day of sampling. Statistical analysis t test unless otherwise specified. 
*
χ
2
 test. 
†
Log-
rank test. 
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Number of patients 117 
Age (mean years ± SD) 66.4 (±15.5) 
Sex, male (%) 50.4% 
APACHE II score 15 (2-40) 
SOFA score 5 (0-18) 
Mortality  
  14 day mortality 12 (10.3%) 
  28 day mortality 15 (12.8%) 
  6 month mortality 23 (19.7%) 
Cause of peritonitis 
  Diverticular disease 30 (25.6%) 
  Surgical anastomosis breakdown 28 (23.9%) 
  Malignancy 14 (12%) 
  Trauma 3 (2.6%) 
  Other/unknown 42 (35.9%) 
Mechanical ventilation 55 (47%) 
Vasopressors 55 (47%) 
Renal replacement therapy 13 (11%) 
Mean arterial pressure (mmHg) 68.2 (14.8) 
 
Table 2. Characteristics of fecal peritonitis patients (all patients) on day 1. 
Data are n (%) unless otherwise specified. APACHE II=Acute Physiology and Chronic Health 
Evaluation II, median (range). SOFA= Sequential Organ Failure Assessment on day of sampling, 
median (range). Arterial pressure, lowest mmHg (SD). 
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Online Data Supplement 
 
Shared and distinct features of the sepsis transcriptomic response to fecal peritonitis and 
pneumonia 
  
Authors: Katie L. Burnham, Emma E. Davenport, Jayachandran Radhakrishnan, Peter 
Humburg, Anthony C. Gordon, Paula Hutton, Eduardo Svoren-Jabalera, Christopher Garrard, 
Adrian V.S. Hill, Charles J. Hinds, Julian C. Knight. 
 
Supplementary Methods 
Supplementary References 
Supplementary Figures 
Figure E1. Schematic of the composition of the discovery and validation cohorts. 
Figure E2. Correlation of differential gene expression between SRS groups in FP and CAP. 
Figure E3. Principal component analysis of FP samples from the discovery and validation 
cohorts showing SRS group assignment 
Figure E4. Comparison of the SRS groups to pediatric sepsis endotypes. 
Figure E5. Expression of SRS_FP model genes in patients moving between SRS groups. 
Figure E6. Correlation between global gene expression and clinical covariates. 
Figure E7. Histogram of results of CAP vs FP differential expression analysis following 
permutation. 
Figure E8. Effect of cell count on differential gene expression analysis between CAP and FP. 
Figure E9. ROC curves for gene set discriminating between CAP and FP. 
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Figure E10. Histogram of RNA sampling day for CAP and FP samples. 
Figure E11. Principal component analysis of FP samples from the discovery and validation 
cohorts combined using ComBat. 
Supplementary Tables 
Table E1. Supplementary data (Excel file) 
Table E2. Participating hospitals involved in patient recruitment and GAinS investigators. 
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Supplementary Methods 
Patient recruitment and exclusion criteria 
Adult patients (>18y) were recruited at 25 UK ICUs between 2006 and 2013 as part of the UK 
Genomic Advances in Sepsis (GAinS) study (www.ukccg-gains.org) (1, 2). Ethics approval was 
granted nationally (REC Reference Number 05/MRE00/38 and 08/H0505/78) and for individual 
participating centers, with informed consent obtained from patients or their legal representative. 
Sepsis was diagnosed according to ACCP/SCCM guidelines, and all patients showed evidence of 
organ dysfunction (1). FP was diagnosed at laparotomy as inflammation of the peritoneal 
membrane secondary to large bowel perforation and fecal contamination (3). CAP was defined 
as a febrile illness associated with a cough, sputum production, breathlessness, leukocytosis and 
radiological features of pneumonia, acquired in the community or within two days of ICU 
admission (4, 5). Exclusion criteria: patient or legal representative unwilling or unable to give 
consent; age <18 years; pregnancy; advanced directive to withhold or withdraw life sustaining 
treatment; admission for palliative care only; or immune-compromise. Demographics and 
clinical covariates were recorded using an electronic case report form which included details of 
the results of microbiological investigations as previously described (1). Equivalent samples 
obtained from 10 patients scheduled to undergo elective cardiac surgery (coronary artery bypass 
grafting/valve replacement/ cardiopulmonary bypass) were used to represent baseline gene 
expression in non-septic individuals. The sample size for the validation cohort was calculated 
based on the original expression data with a group size of 53 giving >90% power to detect a 1.5-
fold change in gene expression at a false discovery rate of 0.05. The primary endpoint for the 
SRS groups was prospectively selected as mortality at 14 days from ICU admission based on 
findings in CAP  patients (1). 
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RNA extraction 
RNA was extracted from the leukocyte samples (stored at -80oC) using the Total RNA Isolation 
Protocol (Ambion). The contents of the filters were collected following lysis with a guanidine 
thiocyanate-based solution. Cellular proteins and DNA were degraded using Proteinase K and 
DNase I respectively and RNA purified using magnetic bead technology. The RNA thus 
obtained was quantified by spectrophotometry (NanoDrop) and quality checks were carried out 
on a small subset of the samples by on-chip electrophoresis (BioRad Bioanalyzer).  
 
Microarray analysis 
Sepsis samples were processed as two cohorts of 227 and 108 samples, with ten samples from 
patients scheduled to undergo elective cardiac surgery also included in the first batch. The 
discovery cohort consists of all samples available for each patient recruited pre-August 2010 that 
passed quality control checks. For the validation cohort, samples from the first available time 
point with high quality RNA were selected for 54 FP patients and 54 approximately age and sex 
matched CAP patients recruited subsequent to the first microarray analysis. The FP samples from 
the discovery and validation cohorts were combined using ComBat (6) (Supplementary Fig. 
E11). Gene expression data for validation cohort CAP samples and the majority of discovery 
cohort CAP samples were published in Davenport et al, 2016 (1). Discovery cohort samples 
were re-run in this study to allow for multiple time points per individual. Microarrays for FP and 
CAP validation cohorts were run at the same time. The traumatic injury and pediatric datasets 
were accessed through NCBI GEO database (accession: GSE36809, GSE26440). The pediatric 
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expression data was log transformed and in parallel re-normalized using the robust multi-array 
average (RMA) for comparative differential expression analysis. 
 
Raw data were prepared using Illumina’s Genomestudio. Data backgrounds were subtracted and 
probes with a detection p-value <0.05 in at least 5% samples retained for downstream analysis in 
the discovery cohort (27,159 probes). The raw data were transformed and normalized using the 
vsn package in R (7). The validation cohort was normalized against the discovery cohort, with 
other QC steps conducted independently.  Following QC including principal component analysis, 
6 samples were removed from the discovery cohort and two from the validation, leaving 221 and 
106 samples respectively. 
 
Statistical analysis 
Demographic and phenotypic data were compared with t-tests for continuous data, and Chi-
square tests for count data. Power calculations were performed using the R package sizepower. 
Differential gene expression was assessed using the limma package (8), which fits a generalized 
linear model to the expression of each gene and employs an empirical Bayes approach to take 
into account the overall variance in the data set. Genes with an FDR <0.05 and a FC >1.5 were 
considered to be differentially expressed. Further investigation of longitudinal gene expression 
profiles was carried out with the timecourse package (9). The enrichment of a given gene set in a 
particular gene expression contrast (e.g. SRS1 vs SRS2 in FP and CAP) was tested using 
ROAST, a rotation-based gene set enrichment test that incorporates effect size and directionality 
(10). Biological pathway enrichment analysis was carried out with Ingenuity Pathway Analysis 
(IPA - QIAGEN, www.qiagen.com/ingenuity QIAGEN Redwood City). Enrichment or over-
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representation of different processes is based on the number of genes identified and the total 
number of genes known to be associated with that process in the reference set (IPA Knowledge 
Base, experimentally observed human molecules and/or relationships) with p value calculated 
using a right-tailed Fisher exact test. Predictors for the SRS_FP and diagnostic models were 
selected using GeneRave (11) from differentially expressed genes with moderate to high 
expression (expression > 6.5) in at least the number of samples in the smaller group. GeneRave 
uses a sparse regression method to select a minimal number of explanatory variables from a large 
number of potential predictors. Patient subgroups were resolved using the FactoMineR package, 
which carries out agglomerative hierarchical clustering using Ward’s method with Euclidean 
distance used to initiate the appropriate number of groups, followed by k-means clustering to 
consolidate group membership. Plotting the within group sum of squares was used to determine 
an appropriate number of clusters. Comparisons to the SRS groups previously observed in CAP 
patients were carried out using a seven gene signature (1). Survival differences were assessed by 
log rank test and cox proportional hazards regression models using the R package survival.  
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25 Intensive Care Units across the United Kingdom 
GAinS Samples 
  
 
 
 
 
 
73 CAP  
 
64 FP  
 
53 CAP  
 
53 FP  
 
  
 
Day 1 40 37 
Day 3 46 34 
Day 5 41 23 
Total 127 94 
Day 1 24 25 
Day 3 20 15 
Day 5 9 13 
Total 53 53 
10 
controls   
       
+ 
Discovery Cohort
ControlsFP patientsCAP patients
Figure E1. Schematic of the composition of the discovery and validation cohorts. 
Number of patients and samples included in the discovery and validation cohorts following 
quality control of gene expression data, categorised by aetiology. Controls are pre-operative 
patients scheduled to undergo elective cardiac surgery. For the investigation of sepsis 
response signatures in FP, all FP patients were used (117 patients). 
Combined FP
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Figure E2. Correlation of differential gene expression between SRS groups in FP and CAP. 
The log fold change for differential expression of each measured gene between SRS1 and SRS2
in FP is plotted against log fold change for the same gene between SRS1 and SRS2 in CAP. The
log fold changes are highly correlated (r 0.79, p <2.2x10-16). Blue colour indicates significant 
differential expression between SRS groups in both CAP and FP;dark green in CAP only; yellow in
FP only; red indicates differential expression in both but in opposite directions; and grey indicates 
that the gene is not significantly differentially expressed. 
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Figure E3. Principal component analysis of FP samples from the discovery and 
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seven gene signature derived from the previously published CAP cohort. 
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Figure E4. Comparison of the SRS groups to pediatric sepsis endotypes. 
(A) Volcano plots of dierential gene expression between pediatric endotype A (n=28), and endotypes B 
and C (n=70). The left hand plot shows the results for log transformed pre-processed data (GSE26440), 
and the right hand plot for RMA normalized data (raw data downloaded from GEO). Red coloring indi-
cates probes with FDR < 0.05 and FC > 1.5. (B) Correlation plots of the dierential gene expression 
outputs. On the left the fold changes of each gene for CAP SRS1 vs 2 is plotted against the fold changes 
for the same genes for the pediatric endotype comparison (using the log transformed data). On the right 
the results for the FP SRS contrast are plotted against the pediatric output. Points are colored according 
to whether the gene was signicantly dierentially expressed in one, both, or neither contrast. Above the 
plots are Venn diagrams showing the overlap in the genes dierentially expressed between pediatric 
endotypes, and between the SRS groups.  The number of genes up- and downregulated are given for 
each comparison, and only genes with expression data in all three cohorts are considered. The SRS 
genesets were found not to be signicantly enriched in the pediatric contrast by ROAST gene set enrich-
ment tests. 
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Figure E5. Expression of SRS_FP model genes in patients moving between SRS groups.
.
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Expression of the six genes selected as predictors of SRS_FP group membership (CD163, 
ZDHHC19, MME, FAM89A, ZBP1, and B3GNT2) in the 11 patients who move between SRS 
groups over time. Each point represents a sample, coloured by SRS group assignment and 
plotted according to time since disease onset. Samples from the same patient are linked, show-
ing the changes in gene expression over time as patients move from one SRS group to another
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Supplementary Figure E7. Histogram of results of CAP vs FP differential expres-
sion analysis following permutation.
In order to determine if the number of genes differentially expressed between CAP and 
FP patients was more than expected by chance, the diagnostic labels were permuted and 
the differential expression analysis repeated 10,000 times. In each case, the number of 
differentially expressed genes (FDR < 0.05, FC >=1.5) was recorded. The comparison for 
the true diagnostic labels had significantly more differentially expressed genes (n=263) 
than would be expected by chance (p=0.0001). The number of permutations returning a 
given number of differentially expressed genes is plotted as a histogram, with the number 
of permutations for each block also shown above each bar. The result for the true 
instance is colored in red. 
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Figure E8. Effect of cell count on differential gene expression analysis between CAP and FP.
The log fold change for differential gene expression of all measured genes between CAP and FP 
accounting for mononucleocyte, polynucleocyte, and lymphocyte count is plotted against the log fold 
change for the same genes between CAP and FP in the minimal model. The log fold changes are 
highly correlated (r 0.986, p < 2.2 x 10-16). Purple colouring indicates significant differential 
expression in both models; pink in the original model only; orange in the model including cell count
only; and grey indicates the gene is not significantly differentially expressed between CAP and FP 
in either model. 
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Figure E9. ROC curves for gene set discriminating between CAP and FP. 
A subset of genes discriminating between CAP and FP samples were identified, comprising 
EPHB1, NQO2, ARG1, HMGB2, FGL2 and GPR162. The performance of the model was tested by 
leave-one-out validation in the discovery cohort and on all samples in the validation cohort. 
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Figure E10. Histogram of RNA sampling day for CAP and FP samples. 
The percentage of samples in the discovery cohort for each day following ICU admission 
are given for CAP (green) and FP (yellow). The left hand plot shows the percentage for all 
available serial samples, and the right hand plot shows the proportions when only the first
available sample for each patient is selected. The CAP and FP subgroups do not differ 
significantly in terms of the proportion of samples from each day of sampling (chi-square test
p-values shown).  
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Figure E11. Principal component analysis (PCA) of FP samples from the discovery and 
validation cohorts combined using ComBat.
Following use of ComBat to account for batch effects between the discovery and validation 
cohorts, there was no clear segregation between the two sets of FP samples.  
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Table E2: Participating hospitals involved in patient recruitment and GAinS Investigators. 
 
Site Principal Investigator Research Nurses/Fellows Other investigators 
Aberdeen Royal Infirmary Professor Nigel Webster  Jane Taylor, Sally Hall, Jenni Addison, Sian Roughton, Heather Tennant   
Broomfield Hospital, Chelmsford Dr John Durcan/  Dr D Arawwawala  
Karen Swan, Sarah Williams, Susan Smolen, Christine Mitchell-
Inwang    
Charing Cross Hospital, London Dr Tony Gordon Emily Errington, Maie Templeton   
Hammersmith Hospital, London Dr Stephen Brett David Kitson, Robert Wilson, Laura Mountford, Juan Moreno   
John Radcliffe Hospital, Oxford Dr Christopher Garrard/ Dr Stuart McKechnie Paula Hutton, Penny Parsons, Alex Smith, Roser Faras-Arraya   
Norfolk & Norwich University Hospital, 
Norwich Dr Simon Fletcher Melissa Rosbergen, Georgina Glister   
Royal Berkshire Hospital, Reading Dr Atul Kapila Nicola Jacques, Jane Atkinson, Abby Brown, Heather Prowse   
Royal Victoria Infirmary, Newcastle Dr Simon Baudouin Charley Higham, Helen Walsh, Verity Calder, Catherine Swan, Heather Payne   
St Bartholomew's/Royal London 
Hospitals Professor Charles Hinds Eleanor McLees, Alice Purdy Dr D. Watson 
Southend Hospital Dr David Higgins Sarah Andrews, Sarah Mappleback   
University College London Hospital 
(UCLH), London Dr Geoffrey Bellingan Jung Hyun Ryu, Georgia Bercades, Susan Boluda   
Royal Blackburn Hospital Dr Anton Krige Martin Bland, Lynne Bullock, Donna Harrison   
Frenchay Hospital, Bristol Dr Jasmeet Soar Sally Grier, Elaine Hall   
Southmead Hospital, Bristol Dr Jasmeet Soar Sally Grier, Elaine Hall   
Royal Sussex County Hospital, Brighton Dr Stephen Drage Laura Ortiz-Ruiz De Gordoa, Sarah Lowes   
Huddersfield Royal Infirmary Dr Peter Hall Jackie Hewlett   
The James Cook University Hospital, 
Middlesbrough Dr Stephen Bonner Keith Hugill, Victoria Goodridge, Louise Cawthor Dr Iain Whitehead 
Kettering General Hospital Dr Phil Watt Parizade Raymode   
Leicester Royal Infirmary Dr Jonathan Thompson Sarah Bowrey, Sandra Kazembe, Natalie Rich, Prem Andreou, Dawn Hales, Emma Roberts   
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Royal Preston Hospital, Preston Dr Shond Laha Jacqueline Baldwin, Angela Walsh, Nicola Doherty   
Queen Elizabeth Hospital, Birmingham Professor Julian Bion 
Joanne Millar, Elsa Jane Perry, Heather Willis, Natalie Mitchell, 
Sebastian Ruel, Ronald Carrera, Elsa Jane Perry, Jude Wilde, 
Annette Nillson, Sarah Lees 
  
St Mary's Hospital, London Dr Martin Stotz Adaeze Ochelli-Okpue   
Wythenshawe Hospital, Manchester Dr Andrew Bentley Katie Mccalman, Fiona Jefferies   
The Whittington Hospital, London Dr Martin Kuper Sheik Pahary   
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